ARTICLE | Clinical News
QGC101: Phase IIa started
July 18, 2016 7:00 AM UTC
Quantum Genomics began the double-blind, placebo-controlled, European Phase IIa QUID HF trial to evaluate 50-500 mg oral QGC101 twice daily for 28 days in about 75 CHF patients with altered cardiac ej...